Biopharma Quarter: Key Trends and Events of the Second Quarter of 2009Decision Resources
September 10, 2009
49 Pages - SKU: DECR2444546
More Biopharmaceuticals reports by Decision Resources
How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis? by Decision Resources
The moderate to severe RA population represents a sizable target for agents acting on the immune system. However, the barriers to entry are ...
U.S. Payer and Prescriber Attitudes Toward Novel Oral, Topical, and Biologic Emerging Agents in the Psoriasis Market: Implications for Market Access by Decision Resources
The psoriasis market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor-alpha (TNF-a) inhibitors ...
How Will U.S. Payers and Prescribers Determine the Success of New Biologics and Oral Entrants and Currently Marketed Biologics in Psoriatic Arthritis and Axial Spondyloarthritis? by Decision Resources
This U.S. Physician & Payer Forum report explores payer and physician dynamics that affect prescribing practices for psoriatic arthritis (PsA) and axial spondyloarthritis ...
Innovative R&D and Dealmaking Opportunities: Oncology Biologics: Novel Therapeutic Antibodies, Proteins, and Peptides by Decision ResourcesSee all reports like this >>
The market for oncology biologics is lucrative; growth in this sector will outpace the overall oncology market, resulting in an increased share of ...
We can help you find what you need. Call us or write us:
Need help in your search?
- Global Markets for Orphan Drugs – Focus on Non-Biologics
- PharmaSphere: Global Biosimilars Strategy - Regulatory Landscape, Key Drivers, Markets and Trends in 2013
- Pharmaceutical Market India: A Comprehensive Industry Analysis
- BioPharmaceutical Industry in China - An In Depth Analysis of Multinational and Chinese Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges
- Competitor Analysis: Therapeutic Proteins – Biosimilars, Biobetters & Biosuperiors